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Abstract 
Background: Metformin is a biguanide used as first line treatment of type 2 diabetes mellitus. When Metformin 
alone is unable to control glycaemic status properly then additional drug needs to be added. Some of the additional 
drugs reduce primarily fasting blood sugar (FBS) and some reduce post prandial blood sugar (PPBS). Voglibose and 
Teneligliptin are primarily capable of reducing PPBS. Overall hyperglycaemia is also controlled by these drugs. In 
this background the present study was planned for comparative study of Voglibose and Teneligliptin to reduce 
HbA1c ongoing Metformin monotherapy. Materials & Methods: It was a hospital based longitudinal interventional 
study among patients attending General Medicine Outpatient Department (OPD) of a Medical College, East 
Medinipur, West Bengal with uncontrolled hyperglycemia and whose HbA1c was above 7 but up to 10% and PPBS 
above 200mg/dl. One group of patients was given voglibose 0.3mg TDS and another group of patients were given 
teneligliptin 20mg BD in addition to previous dose of metformin. After 12 weeks of starting additional drug again 
HbA1c level was assessed for each patient. Results: It was found that mean HbA1c level at the beginning was 
8.89% for voglibose group and 8.83% for teneligliptin group. There was no significant difference between these 
two. After 12 weeks of therapy the mean HbA1c level of voglibose group was significantly higher than teneligliptin 
group. However both groups showed significant reduction of HbA1c as compared to starting. Conclusion: The 
study highlights the ability to reduce HbA1c is more with teneligliptin 20mg BD than voglibose 0.3mg TDS. 
Keywords: Type 2 Diabetes, glycosylated haemoglobin (HbA1c), fasting blood sugar (FBS), post prandial blood 
sugar (PPBS), metformin, voglibose, teneligliptin. 
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original work is properly credited.  
Introduction 
 
Diabetes mellitus is now a days one of the most 
common non communicable disease in India. 
Approximately 8.8% adults aged 20-79 years are 
suffering from diabetes according to a study in 2017 
[1]. Diabetes mellitus has different types of entity of 
which commonest form is Type 2 diabetes mellitus.  
__________________ 
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Type 2 diabetes mellitus is mainly caused by insulin 
resistance and insulin deficiency. Due to impaired 
action of insulin and lack of secretion of insulin there is 
imbalance d metabolism of glucose. Different 
microvascular and macrovascular complications are 
due to cellular damage from chronic hyperglycemia 
resulting from impaired metabolism of glucose [2]. It 
occurs usually at advanced age above the age of 40 
years. However sometimes it can start at early age. 
Different lifestyle factors have an impact on its 
development like lack of physical exercise, eating fast 
food, obesity etc. Treatment primarily consists of 
dietary modifications and physical exercise. But once 
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these measures are unable to control blood sugar 
adequately then drug therapy is initiated. Most 
commonly used drug is Metformin. Metformin is a 
biguanide group of drug. It is used as first line therapy 
of type 2 diabetes mellitus patients [3]. For type 2 
diabetes mellitus Metformin is the drug till it alone is 
able to keep glycaemic level within normal limit. 
However with metformin only many patients with 
T2DM remain inadequately managed, which results in 
progressively declining glycemic control [4]. When 
Metformin alone is not able to control blood glucose 
level properly then additional drug is to be added. The 
use of additional drug must be judicial. It is dependent 
on the level of hyperglycaemia as well as its type. 
Hyperglycaemia may be baseline (fasting) or after 
taking food (post-prandial) or both. Drug therapy for 
treatment of fasting and post prandial hyperglycaemia 
control is different and accordingly drug is chosen. 
Overall glycaemic control is monitored by testing level 
of glycosylated haemoglobin (HbA1c). It should be 
below 7%. Alpha glucosidase inhibitor, dipeptidyl 
peptidase 4 (DPP 4 inhibitor) are some of the drugs 
which are mainly capable of reducing postprandial 
blood sugar (PPBS). But they are also capable of 
reducing overall glycaemic level. So, HbA1c is 
reduced with these two. The present study was aimed 
to find out the comparative ability to reduce 
glycosylated haemoglobin (HbA1c) with voglibose 
(one alpha glucosidase inhibitors) and teneligliptin 
(DPP 4 inhibitor).  
Materials and Methods 
Type of study 
 It was a hospital based interventional longitudinal 
study.  
Study area 
 All patients giving informed consent attending General 
Medicine OPD of ICARE Institute of Medical Sciences 
and Research with diabetes and on Metformin 
monotherapy with uncontrolled hyperglycaemia were 
included in the study till the required sample size is 
achieved. 
Sample size 
Percentage of patients requiring additional anti-diabetic 
medication over Metformin monotherapy is 38% [5, 6]. 
So prevalence of use of additional drug in treating 
Type 2 DM (p) is 38%=0.38  
So, (1-0.38)=0.62 is the number of patients not 
requiring additional drug over metformin (q). 
If we allow error of 10% (L) 
So, using the formula  
4pq/L2= (4*0.38*0.62)/(0.1*0.1)=94 
So, required sample size is 94. 
Considering 10% patients would be lost to follow up or 
discontinue the drug due to different reason, total 
required sample is 94*1.1=103.4. So, 104 patients were 
included in the study. 
Sample design 
About 52 patients were included in each arm: 
voglibose-metformin combination therapy and 
teneligliptin-metformin combination therapy. The 
selection of patients in each arm was done by 
randomization using lottery method.  
Study Technique 
Patients were randomized in two groups. One group 
received teneligliptin 20mg twice daily in addition to 
metformin and the other group received Voglibose 
0.3mg thrice daily in addition to metformin. HbA1c 
was assessed before introduction of additional drug and 
12 weeks after starting additional drug.  
Inclusion Criteria 
 Persons having inadequate glycaemic 
control with HbA1c above 7% but below 
10% 
 Persons on metformin monotherapy 
 Type 2 diabetes mellitus 
 Ambulatory patients 
 Patients having PPBS above 200mg/dl 
 Patients who can be followed up 
Exclusion Criteria 
 Type 1 Diabetes mellitus 
 Isolated rise of fasting blood sugar (FBS)  
 Non ambulatory patients 
 HbA1c above 10% 
Institutional ethics committee permission was taken 
and written informed consent was signed from each 
participants. Statistical test done was unpaired t test.  
Results 
It was a hospital based longitudinal interventional 
study among patients attending General Medicine 
outpatient department (OPD) of a Medical College, 
East Medinipur, West Bengal with uncontrolled 
hyperglycemia and whose HbA1c was above 7 but up 
to 10% and PPBS above 200mg/dl. Table 1 shows 
demographic clinical and laboratory characteristics of 
study participants. It shows that there was no 
significant difference between the baseline 
characteristics of two groups considering their age, sex, 
presence of co-morbidities, fasting and post-prandial 
blood sugar level (FBS and PPBS level). Figure 1 
shows the mean level of glycosylated haemoglobin 
(HbA1c) before starting additional drug. There were 
two study groups. Group 1 received voglibose and 
group 2 received teneligliptin. Mean HbA1c level of 
Group 1 was 8.89% and of Group 2 was 8.83%. There 
was no significant difference between mean HbA1c 
International Journal of Health and Clinical Research, 2020;3(4):128-133                e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Datta et al                International Journal of Health and Clinical Research, 2020; 3(4):128-133 
www.ijhcr.com                              
                    130 
 
level between these two groups. Figure 2 shows mean 
level of HbA1c12 weeks after starting additional drug. 
For Group 1 it was 7.4% and for Group 2 it was 6.6%. 
Now the difference between these two is statistically 
significant (p<0.05) which indicates that people 
belonging to Group 1 were having significantly higher 
level of HbA1c than people belonging to Group 2. So 
after completion of 12 weeks therapy with additional 
drug, people receiving teneligliptin had significant 
lower level of HbA1c than people receiving voglibose. 
Figure 3 shows the change of level of HbA1c with 
these two additional drugs by a line diagram. The 
starting point is before adding additional drug and end 
point is after 12 weeks of continuing additional drug. It 
was seen that with both drugs the level of HbA1c have 
decreased. It was further noticed that the change of 
HbA1c with voglibose was less than change of HbA1c 
with teneligliptin. This difference was also found to be 
statistically significant with p<0.05. Statistical test 
done was unpaired t test. 
  
Table 1: Demographic clinical and laboratory characteristics of study participants 
Patients characteristics Voglibose group Teneligliptin group P value 
Age 
<60 years 36 39 >0.05 
>60 years 16 13 
Sex 
Male 25 28 >0.05 
Female 27 24  
BMI 27.5±4.1kg/m2 27.1±4.4kg/m2 >0.05 
FBS 198±25.8 mg/dl 199±27.4 mg/dl >0.05 
PPBS 296±35.2 mg/dl 288±32.8 mg/dl >0.05 
Presence of co-morbidities   
Hypertension 17 (33%) 19 (37%)  
Dyslipidaemia 14 (27%) 13 (25%)  
CV events 4 (8%) 5 (10%)  
 
 
Figure 1: Mean level of HbA1c before starting additional drug 
 
Figure 2:  Mean level of HbA1c12 weeks after starting additional drug 
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Figure 3: Change of mean HbA1c level with additional drug 
Discussion 
 
Glycosylated haemoglobin (HbA1c) gives an overall 
picture of glycaemic control of past three months (12 
weeks). Target HbA1c should be within 7%. Recent 
studies suggest that very tight glycaemic control is 
often not beneficial and sometimes detrimental for 
overall prognosis of a diabetic patient [7-9]. Rather 
HbA1c between 6.5% and 7% should be beneficial for 
long term prognosis and preventing complications of 
diabetes. If HbA1c persists above 7% then that 
indicates inadequate glycaemic control which is also 
detrimental and promotes different microvascular and 
macrovascular complications of diabetes. Tight 
glycaemic control is often required in different acute 
conditions including infection and sepsis [10-12]. So 
maintenance of optimum level of HbA1c is essential 
[13-14]. Drugs should be adjusted in such a way and 
such a combination so that HbA1c should persist 
between 6.5% and 7%.  
Different studies have been conducted worldwide on 
comparative efficacy of different DPP4 inhibitors with 
voglibose. However head to head study between 
teneligliptin and voglibose is very less. In a study 
conducted by Dabhi AS et al it was seen that with 
voglibose 0.2mg TDS dose mean change of HbA1c 
was -0.38+- 0.04% as compared to -0.95 +- 0.04% in 
group treated with vildagliptin 50mg BD [15]. 
Endpoint HbA1c of <6.5% was also achieved by much 
lower percentage of patients in voglibose group than 
Vildagliptin group (24% compared with 51%). Another 
study by Iwamoto Y et al also finds superiority of 
vildagliptin over voglibose in reducing HbA1c [16]. 
Similarly another study by Matsushima Y et al 
highlights superiority of sitagliptin over voglibose 
[17].DPP-4 inhibitors work in a glucose dependent 
manner, so they are able to lower HbA1c level 
significantly with minimum chance of hypoglycemic 
episode. As a result after the introduction of sitagliptin 
in 2006, the first DPP4 inhibitor, the use of DPP4 
inhibitors is increased remarkably. Mostly they are 
used as add on therapy to metformin or sulfonylurea. 
Among all DPP4 inhibitors sitagliptin was first 
approved in 2006. Gradually more and more DPP4 
inhibitors were developed [18]. But one of the major 
restricting factors of their use is their cost. Due to high 
cost of DPP4 inhibitors poor patients often are unable 
to continue these for long time. Unlike other DPP4 
inhibitors teneligliptin has much lower cost. So in rural 
India its use is popular considering its compliance 
among poor patients. Teneligliptin which is classified 
as peptidomimetic has a unique structure having five 
consecutive rings [19]. So it acts on S2 extensive 
subsite of DPP4 and this interaction increases its 
potency and selectivity [20, 21]. Based on the results of 
a few head-to-head trials or meta-analyses comparing 
the efficacy between DPP-4 inhibitors, there is general 
consensus that the HbA1c-lowering effects of gliptins 
are broadly similar [22, 23].Voglibose belongs to class 
of comparative alpha glucosidase inhibitors which was 
discovered in 1981 [24]. Voglibose causes reversible 
inhibition of membrane bound intestines alpha 
glucosidase which hydrolyze oligosaccharides and 
disaccharides to glucose and other monosaccharides in 
the brush border of small intestine. So voglibose delays 
the absorption and digestion of dietary polysaccharides 
0.00%
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3.00%
4.00%
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by reversibly inhibiting carbohydrate digestive 
enzymes like sucrose, maltose, zomaltose etc 
ultimately resulting in reduction of PPBS as well as 
HbA1c. Teneligliptin is able to lower the PPBS as well 
as HbA1c significantly in 4 weeks compares to 
placebo. Teneligliptin 20mg OD is found to be more 
potent than voglibose 0.2mg TDS [25]. Many new 
drugs have been developed in DPP4 inhibitor class and 
their efficacy studied in detail [26-30]. But head to 
head study between efficacy of cheapest and widely 
used DPP-4 inhibitor in India, i.e. teneligliptin versus 
voglibose is lacking. 
 
Conclusion 
Many new drugs have been developed in DPP-4 
inhibitor class and their efficacy studied in detail. But 
head to head study between efficacy of cheapest and 
widely used DPP-4 inhibitor in India, i.e. teneligliptin 
versus voglibose is lacking. The present study 
highlights the overall HbA1c lowering effect of 
teneligliptin 20mg BD is more than voglibose 0.3 mg 
TDS. But both drugs lower PPBS as well as HbA1c 
level significantly over metformin monotherapy. 
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